ERRATUM

Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

Dian Wang, MD, PhD¹, Qiang Zhang, PhD², Charles D. Blanke, MD³, George D. Demetri, MD⁴, Michael C. Heinrich, MD⁵, James C. Watson, MD⁶, John P. Hoffman, MD⁶, Scott Okuno, MD⁷, John M. Kane, MD⁸, Margaret von Mehren, MD⁶, and Burton L. Eisenberg, MD⁹

¹Medical College of Wisconsin, Milwaukee, WI; ²Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA; ³University of British Columbia and British Columbia Cancer Agency, Vancouver, BC, Canada; ⁴Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; ⁵Portland VA Medical Center and Oregon Health & Science University, Portland, OR; ⁶Fox Chase Cancer Center, Philadelphia, PA; ⁷Mayo Clinic, Rochester, MN; ⁸Roswell Park Cancer Institute, Buffalo, NY; ⁹Dartmouth-Hitchcock Medical Center, Lebanon, NH

ERRATUM TO: ANN SURG ONCOL (2011) DOI 10.1245/S10434-011-2190-5

In the original article, Fig. 1 contained an error. The bottom left box of the figure should have said “Continued Imatinib 600 mg/day for 24 months” not “Continued Imatinib 600 mg/day for 24 hours.”

The figure is reprinted here correctly.

FIG. 1 Schematic representation of the trial. *SD* stable disease, *PR* partial response, *PD* progressive disease

The online version of the original article can be found under doi:[10.1245/s10434-011-2190-5](https://doi.org/10.1245/s10434-011-2190-5).

© Society of Surgical Oncology 2012

Published Online: 7 March 2012

D. Wang, MD, PhD
e-mail: dwang@mcw.edu